Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Jonathan W. Riess, Paul Frankel, David B. Shackelford, Mark Dunphy, Ramsey D. Badawi, Lorenzo Nardo, Simon R. Cherry, Ian R. Lanza, Joel M. Reid, Wilson I. Gonsalves, Charles A. Kunos, David R. Gandara, Primo N. Lara, Edward M. Newman, Paul K. Paik
Topics & Concepts
KRASMedicineTolerabilityAdenocarcinomaOncologyClinical endpointLung cancerPI3K/AKT/mTOR pathwayCancer researchInternal medicineCancerAdverse effectColorectal cancerClinical trialBiologySignal transductionGeneticsLung Cancer Treatments and MutationsGenomics, phytochemicals, and oxidative stressLung Cancer Research Studies